GRM5 and Alzheimer disease: Moreover, the pharmacological blockade of mGluR5 using the mGluR5-selective negative allosteric modulator CTEP, reduces the development of AD-like neuropathology; specifically reducing Aβ soluble oligomer and plaque deposition, in both APPswe/PS1ΔE9 and 3xTg-AD (3xTg) mouse models [12].